Bristol-Myers Squibb: Multiple Myeloma trials

The registry lists 149 Multiple Myeloma studies with Bristol-Myers Squibb as lead sponsor. 10 are open to participants now and 45 have results posted.

Phase 1 51Phase 2 39Phase 3 32No phase 41(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02692339
• Study of bb2121 in Multiple MyelomaCompletedNCT02658929Phase 1
• A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02616640Phase 1
• A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in KoreaCompletedNCT02556905
• Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical PracticeCompletedNCT02555839
• An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide.CompletedNCT02528838
• Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple MyelomaTerminatedNCT02400242Phase 1
• Post-authorisation Study of Biological Relapse in Patients With Multiple MyelomaTerminatedNCT02394210
• A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TRStatus unknownNCT02387879
• Expanded Access Treatment Protocol CA204-143No longer availableNCT02368301
• Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Phase 2
• A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple MyelomaCompletedNCT02252263Phase 1
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple MyelomaCompletedNCT02189343Phase 1
• A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.CompletedNCT02164955
• Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological MalignanciesCompletedNCT02164071
• Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in MyelomaWithdrawnNCT02155634Phase 3
• Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMMCompletedNCT02112175Phase 3
• Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple MyelomaCompletedNCT02103335Phase 1
• Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal InsufficiencyCompletedNCT02045017Phase 2
• Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309
• Pharmacokinetic Study of Thalidomide in Subjects With Multiple MyelomaCompletedNCT01937442Phase 1
• Phase 1 Study of CC-486 in Japanese Subjects With Hematological NeoplasmsTerminatedNCT01908387Phase 1
• Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)Active, not recruitingNCT01838512
• A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in TaiwanCompletedNCT01752075
• Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple MyelomaApproved for marketingNCT01632826
• Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Phase 2
• Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple MyelomaCompletedNCT01583283Phase 1
• Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)CompletedNCT01575925Phase 1
• Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple MyelomaCompletedNCT01568294Phase 1
• Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01497093Phase 1
• Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic MalignancyWithdrawnNCT01452334Phase 1
• Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple MyelomaCompletedNCT01421524Phase 1
• Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT01359657Phase 1
• Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple MyelomaCompletedNCT01323751Phase 1/2
• Connect® MM- The Multiple Myeloma Disease RegistryTerminatedNCT01081028
• Multiple Ascending Dose (MAD) Combination in Subjects With Multiple MyelomaCompletedNCT00884546Phase 1
• Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple MyelomaCompletedNCT00761722Phase 1
• NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or LymphomaCompletedNCT00667082Phase 1
• Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple MyelomaCompletedNCT00657488Phase 2/3
• Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple MyelomaCompletedNCT00555100Phase 1
• A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First RelapseCompletedNCT00546780Phase 3
• A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple MyelomaCompletedNCT00514371Phase 2/3
• Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple MyelomaCompletedNCT00452569Phase 3
• A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)CompletedNCT00091624Phase 1
• Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT00065351Phase 2
• A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple MyelomaCompletedNCT00057564Phase 3
• A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple MyelomaCompletedNCT00051116Phase 2
• CDC-501 Therapy in Relapsed or Refractory Multiple MyelomaCompletedNCT00044018Phase 2